Fycompa – Important Safety Information

January 6, 2022

FYCOMPA® (perampanel) is indicated in patients with epilepsy aged 4 years and older for partial‑onset seizures (POS) with or without secondarily generalized seizures and adjunctive therapy for patients aged 12 years and older for primary generalized tonic‑clonic (PGTC) seizures.

See full prescribing information for complete boxed warning HERE:


• Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation
and threats have been reported in patients taking FYCOMPA (5.1)
• Monitor patients for these reactions as well as for changes in mood, behavior, or personality that are not typical for the patient, particularly
during the titration period and at higher doses (5.1)
• FYCOMPA should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening.

Related Posts

Recall – Vigabatrin for Oral Solution USP